Showing 126–150 of 184 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Siri Chandana Gampa, Sireesha V. Garimella
…ine to maximize cancer prevention, screening, and treatment regimens. These applications include risk assessment, screening and early detection, accurate diagnosis, patient prognosis, therapy prediction, cancer surveillance and response monitoring.
Tushar Garg
…that patients receive and take their specialized antibiotic regimens. The DOTS-Plus program for patients with drug-resistant TB described in this study provides individualized, patient-centered care in a community-based, outpatient, and low-resource environment. With this program…
Moamen Al Zoubi
We describe a case of native tricuspid valve endocarditis and pacemaker infection secondary to M. fortuitum. We also review the published literature on cardiac device–associated infections and native valve endocarditis caused by M. fortuitum. Endocarditis and cardiac device infec…
Justice K. Boakye-Appiah, Belinda S. Hall, Rajko Reljić, Rachel E. Simmonds
Abstract Buruli ulcer (BU), one of the skin-related neglected tropical diseases (skin NTDs), is a necrotizing and disabling cutaneous disease caused by subcutaneous infection with Mycobacterium ulcerans. Leading on from the World Health Organization’s (WHO) establishment of a glo…
Ranthilaka R. Ranawaka, Vesna Pljakoska, Andrej Petrov
Leprosy, also known as Hansen’s disease, is a chronic infectious disease caused by Mycobacterium leprae (M. leprae), an acid-fast, rod-shaped bacillus. The disease primarily affects the peripheral nerves, skin, upper respiratory tract, eyes, and nasal mucosa. Leprosy may be compl…
Dilvani Oliveira Santos, Paulo R. Z. Antas
Tuberculosis (TB) is a contagious infectious disease that is a major cause of morbidity, being one of the top 10 causes of death worldwide, and the leading one from a single infectious agent. Also called “White Plague” in the past, TB is an airborne disease, propagated when multi…
Karuna Gokarn, Ramprasad B. Pal
Background: The problem of drug-resistant Mycobacterium tuberculosis (M.tb) is alarming and therefore there is an immediate need for alternative or complementary drugs. This could be achieved by repurposing existing FDA-approved drugs. In this study, the anti-tuberculosis activit…
Charlotte A. Roberts, Peter Davies, Kelly E. Blevins, Anne C. Stone
…ble, drug resistance is a particular challenge in treatment regimens. In 2014 and again in 2018, the World Health Organization’s <italic>The End TB Strategy</italic> was approved by the World Health Assembly, with the goal of ending the TB epidemic by 2030 (World Health Organizat…
Gwen A. Huitt
…imization. Clarithromycin, drug is rarely used in treatment regimens for infections due to M. tuberculosis, but is commonly used to treat mycobacterial infections other than tuberculosis.
V. R. Karthikayan, Anil Singh
… is the cornerstone of management and standard chemotherapy regimens are still evolving. Small bowel adenocarcinoma most commonly presents as a solitary infiltrating mass and hence our case is very unique in its presentation as multiple malignant strictures in jejunum and ileum. …
Patrick Howlett, Robert J. Wilkinson, Ben J. Marais
…berculosis treatment, TB and HIV, TB in Children, Treatment regimens, Multi-drug resistant and extensively drug resistant TB , Lessons learned in TB treatment and control
Cynthia A. Bonville, Joseph B. Domachowske
…on and treatment, programs to ensure adherence to treatment regimens, and comprehensive contact tracing to identify individuals who have been exposed to active disease.
Keertan Dheda, Aliasgar Esmail, Anzaan Dippenaar, Robin M. Warren, Jennifer Furin, et al.
This chapter discusses the clinical perspective and focuses on the clinical and molecular epidemiology, diagnosis, and clinical management of drug-resistant tuberculosis (DR-TB). Tuberculosis (TB) is far from eradicated and remains the foremost single infectious disease killer wo…
Md Abdur Rahim, Hoonhee Seo, Indrajeet Barman, Mohammed Solayman Hossain, Md Sarower Hossen Shuvo, et al.
Tuberculosis, primarily caused by, is an airborne lung disease and continues to pose a significant global health threat, resulting in millions of deaths annually. The current treatment for tuberculosis involves a prolonged regimen of antibiotics, which leads to complications such…
Tuberculosis (TB) infects one-third of the world population, and more than 80% of patients with active tuberculosis are HIV positive and at high risk of developing active disease. Intraocular TB constitutes a very small percentage of uveitis cases in North America and Europe (abo…
Umashri Sundararaju, Shanmathi Subramanian, Hamrish Kumar Rajakumar
…infants. Future research should focus on optimizing steroid regimens, understanding the long-term effects of corticosteroid use during pregnancy, and developing personalized treatment strategies to improve maternal and fetal outcomes in VKH management.
Shamila D Alipoor, Julia Guthrie, Lina Davies Forsman, Andrew R Di Nardo, Susanna Brighenti
…a major global health challenge, with multi-drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis, these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribu…
Dan Ye, Ning Gan, Yang Yang, Zhentao Fei, Huarui Liu, et al.
…rted in the literature, Among 160 cases detailing treatment regimens, 152 cases (95%) underwent anti-tuberculosis therapy, and eight were treated with adrenalectomy alone. Cortisol replacement therapy was administered to 106 cases (66%). Prognostic data from 119 cases reported th…
Katarina Niward, Clara Braian, Gustav Svärdhagen, Daniel Augustinsson, Isabelle Öhrnberg, et al.
Developing shorter treatment regimens for tuberculosis requires careful characterization of the clinical phenotype, which is defined by patient characteristics, radiological extent of disease, mycobacterial burden, drug susceptibility, and host response. Advances in 'omics and mo…
Shweta Tiwari, Ankit Kumar Singh, Aarshu Acharya, Joyabroto Ghosh, Rashmi Prabha Singh
…echanisms of multidrug resistance and ineffective treatment regimens have driven advances in drug development and alternative therapeutics. New molecules that can potentially disarm MTB have been explored, including SQ109, GuaB2, Q203, Largazole, and Auranofin. In addition, natur…
Qamar Abuhassan, Mohamed Abu Shuheil, Narinderjit Singh Sawaran Singh, Praharshkumar B Raj, Subbulakshmi Ganesan, et al.
…y integrating mRNA constructs into heterologous prime-boost regimens and host-directed therapies, the field moves toward a precision vaccinology framework capable of curtailing the TB epidemic.
Dirk Schnappinger, Steven J Berthel, Helena I M Boshoff, Inna V Krieger, Paridhi Sukheja, et al.
…porting development of both pan-TB and treatment-shortening regimens. This paradigm is adaptable to other bacterial pathogens and is designed to improve evidence-based decision-making in antibacterial drug discovery.
Ingrid Burkhardt, Florian Götzinger, Lahia Iipumbu, Elizabeth Whittaker, Gunar Günther, et al.
…escents with MDR-TB. The recently introduced short-all oral regimens provide safer and shorter treatment options. The effectiveness of levofloxacin as MDR-TB preventive treatment has been demonstrated. However, wide implementation of such new and advanced tools is still pending a…
Kelsey L Briggs, Betsy J Russell, Peter Warner, Ken Duncan, Steven J Berthel
Developing tuberculosis drug regimens requires coordinated discovery of multiple, mechanistically distinct agents, which challenge traditional single-asset models. The Tuberculosis Drug Accelerator (TBDA) was established as a multi-organizational consortium to enable collaborativ…
Geraint Rhys Davies
…nt translational impact in the development of new treatment regimens for TB. This article is part of the Theo Murphy meeting issue 'Evaluating anti-infective drugs'.